following the FDA. quarter, everyone. the the IMPALA Last Hello, And our Rob. X of with we design expected you, discussions outlined Thank study confirmatory
As that the from through noted working additional FDA the have and study. and some EMEA. That we suggestions done details of incorporates was are a we now that protocol
information of sample in and XX will blind, study X New XXX we double study the first will efficacy the XXXX. endpoints for size is be expect that a patients with quarter be by It primary week placebo-controlled the the to of IMPALA analyses. start the assessed that
drug, in arms, than be as XXX be intended treatment However of the be XX-weeks better administered is the or micrograms arms will long-term will patients to treatment two one of chronically. follow which safety the over randomized Patients well period, period of in administered more daily. once placebo administered no both effects all which control dosed into daily consumer At the control placebo once assess defeat administered open durability once effect rolled label the XX-weeks daily. of to period, will as micrograms serum will in end on
period the regulatory believe follow on study. as encourage offers participate authorities, by for requested enrollment, not we it While incentive will an to patient in patients
safety capacity provide monoxide a total endpoints being be it the St. to on score. IMPALA patient endpoint secondary to the carbon of Those primary of The function capacity long-term useful exercise using test. Additionally, drug. benefit for Respiratory SGRQ be treadmill score evaluated. of and DLCO. or will George's diffusing SGRQ Questionnaire direct test Three or activity will the information competence will X measure lung study designed
endpoint of conducted with X IMPALA in week after and From XX% size multiple the is EMEA, efficacy study primary to X.X% endpoints. powered the statistical a sample and across change the show FDA to of DLCO supported XXX winning be improvement meaningful With placebo of to clinically the DLCO study from a drug IMPALA X wing the by be locations. considered on has by will baseline. need the difference XX evidence
your across would on required be efficacy. secondary and to the is to transmit While statistical considered data endpoints its endpoints the event assess not secondary tertiary
procedure placebo. till study measured of IMPALA to XXXX.The endpoint DLCO and studies testing the first cloud which time improvement some in a of for in live at AA And testing X is case between me of in all Due it sites the study study. repeated DLCO Let the DLCO we is the at standardize in difference test data. IMPALA of that over ones the gradient treatment measure. X variety study relation will points. taking in IMPALA. clinical practice. widely IMPALA IMPALA AA used gas lung [indiscernible] be DLCO in test over the the the is goes the X.X% be more X In XX. the the in measurements, regimen endpoint not mainly standardized second is will will reasons, to the can showed for it when and primary week a the exchange which using those have IMPALA now function and use in DLCO X This compare elements separation by placebo with expect of completed AA same in as Therefore, studies IMPALA primary both June the equipment gradient gradient DLCO let key variability IMPALA less
the and a gradient for in we IMPALA to gradient placebo be come data not gas could oxygen and the we AA to oxygenation come that make IMPALA between than in X measurement. addresses altered be in by tested which of gas Additionally, can by a oxygen believe study sampling, consistent tool patients blood measurement measured to the short oxygen study, DLCO pulseoximetry point. use as period. be will testing missing. will the the sure by calculation. supplemental such on Situations more the drug patients off factor can the the patients are superior factor stabilized analyzed off the in results. was if patients time and come given that difference be DLCO for either off remain they to on but standardized IMPALA blood The to IMPALA conduct before is improve X would oxygen, measurement protocol during either criteria as allowed gradient explanatory X exchange that I the specifying like The IMPALA during these that for key IMPALA and not end supplemental oxygen supplemental oxygen an need confounding study enrolled discontinue. overflow acknowledge exchange supplemental and of we patients in ensure could use our able not will study The impacted confounding AA supplemental that
and the the study. for a to possible the short However, be will progress period it use is come patient supplemental not point placebo study able to the oxygen arm time off the particularly time that in in patients during can
as and Now IMPALA. which all use dose endpoints. the in was shows in SGRQ let’s I a well. as components. endpoint total resulted endpoint outer components, score nice - which and secondary a and the domestic with we secondary IMPALA, the procedure. symptoms, impact. three have as are and SGRQ is They before, and it activity most X, of SGRQ secondary endpoint, should be mentioned total a daily And nice review the X activity will aPAP X IMPALA the a IMPALA IMPALA separator and separation applicable it separation in structure another the regimen and also secondary for as between to IMPALA make
the medical stretched to as capacity. test assess is functional a X a The [indiscernible]. IMPALA of treadmill patient a is to stressed. key of study patients. aspect an the lavage because treatment minute secondary are is a showed the determining mentioned function, Which important in but and until is IMPALA expected contrast, treadmill we to standardized gradually to the speed lung secondary in In endpoint. for in six a as it use the be using test capacity patients test As Whole wasn't increasing aPAP the discriminatory, walk treadmill a distance the slope the treadmill capacity endpoint. improvement excise Exercise study test trend,
study, recorded measured lung XX%. blind be whole as an patients percentage IMPALA IMPALA The whole lavage point. double X endpoint. period in had the lung study lavage IMPALA will first secondary In at as lung whole key who treatment exploratory The end in X. a to lavage of - about we IMPALA
regimen. only in patients the study with drug XXX each. lavage active contrast, centers and all The Canada, XX three have was of had once in as Operationally, have We IMPALA a and Because XX the treatment one to close total arms study one possible. with is sites Japan, countries, X plans The of XX and affect select across policy countries. countries conducted sites the a patients better in in across U.S., compare between dosing whole Europe. of daily lung will IMPALA arm, the to compared regimen. treatment together treatment South nearly the as placebo. including regiment Korea, have about IMPALA dose In expect X XX under of In more dosing the XX approximately contrast, It intermittent two treatment statement total to study to should XX conducted and arms, each. IMPALA patients patients try IMPALA X at in patients open XXX at will
centers overtime. are rate centers per gradually at ramped However, once. U.S. to Once Xeight enrollment XX in are including added for open, not And sites patients study were up activated IMPALA approximately patient Peak month. enrollment study consequently, the later. all that
believe try Given that we of the constantly IMPALA around Canada. conducted We will X can we centers and sites And efficiency. enroll and plan X the of with U.S. our same be with that relationships and IMPALA to opening experience XX the of many study time. greater study. all in the IMPALA which
initiated enrollment be have and better to regard. clinical position There which Once favorable company timing the competent of answer today questions for progress centers a the in are approved recruiting, country, aPAP all regarding for not in will in IMPALA not any will trials, this no recruitment. any started under for we We completion. is
Additionally, IMPALA-X treated are patients with the continuation Molgradex weekly the approximately IMPALA study we of where micrograms stalking of intermittent XX regimen. study, the XXX are
be IMPALA-X patients study. for may X IMPALA from eligible the Some come
had last and that regulators this on study Constructive we the with matters productive have which keep you with will design of Over we Japanese ongoing, discussions confident. and have the in updated few Europe, most are in in regard. culminated regulators the IMPALA the we U.S. months, conversations
for to These are want listening organization session incorporate with patient pleased or as the for my foundation partnership a on like this rare national FDA mind agency sessions that focused see well. disorders, I we good As I the mention and to rare low PAP in that it engage is what tack. the patients agency and this recently on to disease, rare remarks, a is disease advocates, of end to directly for hand hosted with to The as the flow you with our the information from living call to of with people this serious decease. to of Thank continually lot are session could your for this at happy will the who stories will research. today. provide the you a into their those is powerful with a treatment drive that It to heart over that time stories of update. regulators. will content. And we the PAP Patients hear [indiscernible] Dave I financial share
